OGT will develop the 60-mer oligonucleotide microarray.

Oxford Gene Technology (OGT) and the Wellcome Trust Sanger Institute will develop a single-platform microarray to test for genetic defects in unborn children. The goal of is to develop and validate a microarray to specifically target a number of key prenatal syndromes.

OGT will design and develop the  60-mer oligonucleotide microarray using its ink jet in situ synthesis platform and work. The company will work with the Sanger Institute’s clinical network to target the most appropriate syndromes.

Previous articleCellzome and J&JPRD Extend Alzheimer’s Partnership
Next articleAxxam and Boehringer Ink Two Drug Research Agreements